
Boundless Bio, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Boundless Bio is a biopharmaceutical company developing therapies targeting extrachromosomal DNA (ecDNA)-driven cancers, a mechanism of tumor cell gene amplification linked to aggressive disease and treatment resistance. The company's lead programs are designed to selectively target cells harboring ecDNA to treat cancers that are difficult to address with existing therapies.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| TANG KEVIN10% Owner | Buy | $277K | 118,185at $2.34 | Oct 16, 2026 |
| TANG KEVIN10% Owner | Buy | $30K | 12,790at $2.34 | Oct 19, 2026 |
| TANG KEVIN10% Owner | Buy | $43K | 18,279at $2.33 | Oct 19, 2026 |
| TANG KEVIN10% Owner | Buy | $521 | 220at $2.37 | Oct 20, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable BOLD activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.